Safety and Pharmacokinetics of Long-Acting Monoclonal Antibodies Tixagevimab and Cilgavimab (AZD7442) in a China Phase 2 Study and Evaluation of Asian Race Effect [0.03%]
Tixagevimab和Cilgavimab(AZD7442)中国区二期研究的安全性与药代动力学特征及评估亚洲种族效应
Jing Zhang,Huixia Zhang,Yajuan Zhang et al.
Jing Zhang et al.
Safety, pharmacokinetics, and impact of race of pharmacokinetics on monoclonal antibodies tixagevimab and cilgavimab (AZD7442) were assessed in Chinese adult participants in a Phase 2, randomized, double-blind, placebo-controlled trial. In ...
Relative Bioavailability, Food Effect, and Bioequivalence Studies to Assess a New Zanubrutinib 160-mg Tablet: Results From 2 Phase 1 Studies in Healthy Volunteers [0.03%]
zanubrutinib 160毫克片剂的相对生物利用度、饮食影响和生物等效性研究：健康志愿者中2项1期研究的结果
Bilal Tariq,Chester Lin,Vaibhav Mundra et al.
Bilal Tariq et al.
Zanubrutinib is a next-generation Bruton tyrosine kinase inhibitor approved for treating B-cell malignancies. Two phase 1 studies evaluated a new 160-mg zanubrutinib tablet versus 80-mg capsules. In study BGB-3111-115 (n = 43), a randomized...
Pharma's AI Inflection Point: What Does It Mean for Early Phase Clinical Development? [0.03%]
制药业人工智能拐点：这对早期临床开发意味着什么？
Amalia M Issa
Amalia M Issa
Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants [0.03%]
口服Orforglipron的体内处置及绝对生物利用度研究
Bridget L Morse,Shobha Bhattachar,Xiaosu Ma et al.
Bridget L Morse et al.
Orforglipron is a non-peptide, oral glucagon-like peptide 1 receptor agonist under development for glycemic control in adults with type 2 diabetes and weight management in people with obesity. Two phase 1, open-label studies evaluated the d...
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First-in-Human Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Escalation Phase 1 Study [0.03%]
贝西萨林在健康志愿者中的安全性、耐受性、药代动力学、药效学及食物影响：一项首次人体随机双盲安慰剂对照递增剂量I期试验
Rosa Chan,Chad Orevillo,Gale O&#x;Connell et al.
Rosa Chan et al.
Bexicaserin (LP352) is a selective 5-hydroxytryptamine 2C (5-HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double-blind, placebo-controlled, single ascending dos...
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double-Blind, Placebo-Controlled Study [0.03%]
一项随机、双盲、安慰剂对照研究：贝西萨林在健康志愿者中多次给药和剂量递增的耐受性、药动学和药效学研究
Jonathan Williams,Rosa Chan,Chad Orevillo et al.
Jonathan Williams et al.
Bexicaserin (LP352) is a selective superagonist of the 5-hydroxytryptamine 2C (5-HT2C) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double-blind,...
Comparative Bioequivalence Study of 2 Clevidipine Formulations in Healthy Chinese participants: A Single-Dose, 2-Period Crossover Trial [0.03%]
健康中国受试者中两种氯索必利制剂的生物等效性比较研究：一项单次给药、两周期交叉试验
Zhuo Chen,Fengshan Li,Qin Yu et al.
Zhuo Chen et al.
Clevidipine emulsion is an intravenous antihypertensive agent indicated for acute blood pressure control when oral therapies are contraindicated or ineffective. To address this gap in availability, a randomized, 2-period, 2-sequence crossov...
Computer-Aided Algorithmic Approaches to Drug Development for Multi-Mutant HIV-1 Reverse Transcriptase [0.03%]
计算机辅助的算法方法开发用于多突变HIV-1逆转录酶的药物
Akmal Zubair,Muhammad Ali,Mahmoud M Hessien
Akmal Zubair
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) inhibit the activity of the reverse transcriptase enzyme in HIV, representing a significant advancement in antiviral therapy. The emergence of antiviral-resistant strains of HIV-1 pos...
Dual Therapy Triumph: Yuquan Capsules and Metformin in Combating Type 2 Diabetes Mellitus Disorders [0.03%]
玉泉胶囊联合二甲双胍治疗2型糖尿病及其并发症临床优效性研究
Lufan Zhang,Qinqin Fan,Liying Chen
Lufan Zhang
Glucose and lipid metabolism disorders significantly contribute to vascular damage and poor outcomes in patients with diabetes. This study aims to evaluate the combined effects of Yuquan capsules and metformin on glucose and lipid metabolis...
Bioequivalence and Food Effect Assessment of Apalutamide Tablets Relative to Erleada in Healthy Chinese Male Participants [0.03%]
阿帕他胺片与Erleada®在中国健康男性受试者中的生物等效性及饮食影响评价临床研究
Ning Li,Xuanxuan Wang,Rui Li et al.
Ning Li et al.
Apalutamide, a second-generation non-steroidal androgen receptor inhibitor, is indicated for the treatment of non-metastatic castration-resistant and metastatic hormone-sensitive prostate cancer. A study was conducted to investigate the pha...